Mitotic inhibitor

From Wikipedia, the free encyclopedia
  (Redirected from Antimitotic agent)
Jump to: navigation, search
The structure of paclitaxel, a widely used mitotic inhibitor.

A mitotic inhibitor is a drug that inhibits mitosis, or cell division. These drugs disrupt microtubules, which are structures that pull the cell apart when it divides. Mitotic inhibitors are used in cancer treatment, because cancer cells are able to grow and eventually spread through the body (metastasize) through continuous mitotic division and so are more sensitive to inhibition of mitosis than normal cells. Mitotic inhibitors are also used in cytogenetics (the study of chromosomes), where they stop cell division at a stage where chromosomes can be easily examined.[1]

Mitotic inhibitors are derived from natural substances such as plant alkaloids, and prevent cells from undergoing mitosis by disrupting microtubule polymerization, thus preventing cancerous growth. Microtubules are long, ropelike proteins that extend through the cell and move cellular components around. Microtubules are long polymers made of smaller units (monomers) of the protein tubulin. Microtubules are created during normal cell functions by assembling (polymerizing) tubulin components, and are disassembled when they are no longer needed. One of the important functions of microtubules is to move and separate chromosomes and other components of the cell for cell division (mitosis). Mitotic inhibitors interfere with the assembly and disassembly of tubulin into microtubule polymers. This interrupts cell division, usually during the mitosis (M) phase of the cell cycle when two sets of fully formed chromosomes are supposed to separate into daughter cells.[2][3]

Examples of mitotic inhibitors frequently used in the treatment of cancer include paclitaxel, docetaxel, vinblastine, vincristine, and vinorelbine.[1] Colchicine is a mitotic inhibitor used in the treatment of gout.[4]

Use of mitotic inhibitors in cytogenetics[edit]

Main article: Cytogenetics

Cytogenetics, the study of chromosomal material by analysis of G-Banded chromosomes, uses mitotic inhibitors extensively. In order to prepare a slide for cytogenetic study, a mitotic inhibitor is added to the cells being studied. This stops the cells during mitosis, while the chromosomes are still visible. Once the cells are centrifuged and placed in a hypotonic solution, they swell, spreading the chromosomes. After preparation, the chromosomes of the cells can be viewed under a microscope to have the banding patterns of the chromosomes examined. This experiment is crucial to many forms of cancer research.

Specific agents[edit]

Taxanes[edit]

Main article: Taxanes

Taxanes are complex terpenes produced by the plants of the genus Taxus (yews). Originally derived from the Pacific yew tree, they are now synthesized artificially. Their principal mechanism is the disruption of the cell's microtubule function by stabilizing microtubule formation. Microtubules are essential to mitotic reproduction, so through the inactivation of the microtubule function of a cell, taxanes inhibit the cell's division.

Vinca alkaloids[edit]

Skeletal formula of vinblastine
Main article: Vinca alkaloids

Vinca alkaloids are amines produced by the hallucinogenic plant Catharanthus roseus (Madagascar Periwinkle). Vinca alkaloids inhibit microtubule polymerization, thereby inhibiting mitosis.

Colchicine[edit]

Main article: Colchicine

Colchicine is an alkaloid derived from the autumn crocus (Colchicum autumnale). It inhibits mitosis by inhibiting microtubule polymerization. While colchicine is not used to treat cancer in humans, it is commonly used to treat acute attacks of gout.[4]

Podophyllotoxin[edit]

Podophyllotoxin and Podophyllin, derived from the may apple plant, are used to treat viral skin infections.

Griseofulvin[edit]

Griseofulvin, derived from a Penicillium mold, is an antifungal drug.

See also[edit]

References[edit]

  1. ^ a b "What Are the Different Types of Chemotherapy Drugs?". American Cancer Society. Retrieved 2007-08-05. 
  2. ^ "Definition of mitotic inhibitor". National Cancer Institute. Retrieved 2007-08-05. 
  3. ^ "Treatment Options: Mitotic Inhibitors". Drug Digest. Archived from the original on 2007-02-16. Retrieved 2007-08-05. 
  4. ^ a b "Pharmacology of Colchicine". Cyberbotanica. University of Texas. [dead link]
  5. ^ Saville, M. W.; Lietzau, J.; Pluda, J. M.; Wilson, W. H.; Humphrey, R. W.; Feigel, E.; Steinberg, S. M.; Broder, S.; Yarchoan, R.; Odom, J.; Feuerstein, I. (1995). "Treatment of HIV-associated Kaposi's sarcoma with paclitaxel". Lancet 346 (8966): 26–28. doi:10.1016/S0140-6736(95)92654-2. PMID 7603142. 
  6. ^ Lyseng-Williamson, K. A.; Fenton, C. (2005). "Docetaxel: A Review of its Use in Metastatic Breast Cancer". Drugs 65 (17): 2513–2531. doi:10.2165/00003495-200565170-00007. PMID 16296875. 
  7. ^ Clarke, S. J.; Rivory, L. P. (1999). "Clinical Pharmacokinetics of Docetaxel". Clinical Pharmacokinetics 36 (2): 99–114. doi:10.2165/00003088-199936020-00002. PMID 10092957. 
  8. ^ a b c d "Vincristine (Oncovin)". Retrieved 2007-08-05.